Join the 'Thrombocytopenia' group to help and get support from people like you.
Posted 20 Nov 2012 by Drugs.com
LONDON, Nov. 19, 2012 – GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Promacta for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. Promacta is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. Promacta in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure. There are limitations to the use of Promacta in patients suffering from chronic hepatitis C-associated thrombocytopenia. These include: Promacta should not be used in an attempt to normalize platelet counts; Promacta should be used only in patients with ch ... Read more
Ask a Question
Related Condition Support Groups
Related Drug Support Groups
prednisone, dexamethasone, Decadron, Deltasone, Promacta, Sterapred, eltrombopag, Dexpak Taperpak, Sterapred DS, view more... Liquid Pred, Adrenocot, Dexone, Cerezyme, Prednicen-M, Orasone, Hexadrol, Meticorten, Prednicot, imiglucerase, Decaject, Dalalone, Baycadron, Dexamethasone Intensol, Decadron-LA, Solurex LA, Dexasone LA, Dexasone, Dexacort-LA, De-Sone LA, Dexacen-4, Dexone LA, Medidex LA, Medidex, Dexacorten, Primethasone, Solurex